person
Delphine L.
- Country
- France
- Department
- Departement d'oncologie médicale
Research Overview
assignment
18
Clinical Trials ·
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- Phase III Randomized, Double-Blind Study of Pembrolizumab with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in High-Risk ER+/HER2- Breast Cancer
- Phase 3 Randomized Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in HR+/HER2- Metastatic Breast Cancer
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
231
Sites with multiple studies
Has run more than one trial at 231 of 468 partner sites.
Specializations
Breast Cancer Specialization
This investigator focuses extensively on various forms of breast cancer treatment, particularly specializing in HER2-positive and triple-negative breast cancer (TNBC) therapeutics.
- Early-stage HER2+ breast cancer management
- Advanced metastatic breast cancer treatment
- Triple-negative breast cancer interventions
Immunotherapy Expertise
The investigator has significant experience in immunotherapeutic approaches for breast cancer treatment, including work with various immunotherapy agents and combinations.
- Combination immunotherapy protocols
- Neoadjuvant immunotherapy applications
- Novel immunotherapy agents
Targeted Therapies
Expertise in targeted therapeutic approaches for breast cancer, including work with antibody-drug conjugates and specialized treatment protocols.
- HER2-targeted treatments
- Hormone receptor-positive therapy
- Novel therapeutic combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.